December 2025—Clear Labs announced at the Association for Molecular Pathology annual meeting (Boston, Nov. 11–15) its collaboration with Labcorp to automate PGDx kitted oncology NGS assays on the Clear Dx platform. Clear Labs says the collaboration aims to develop streamlined, end-to-end workflows that help laboratories improve efficiency, consistency, and throughput while laying the groundwork for future adoption across a range of genomic applications. This new workflow will expand Clear Labs’ infectious disease applications into oncology testing.
The company is also integrating Pillar Biosciences’ OncoReveal Solid Tumor 22 Gene panel on the Clear Dx platform. The panel is for research use only and uses Pillar’s proprietary stem-loop inhibition-mediated amplification (SLIMamp) technology. The Clear Dx platform is for research use only and not for use in diagnostic procedures.
Clear Labs, 650-257-3304